Loading
A phase 2 trial of Pegfilgrastim and Darbepoetin alfa in Breast cancer, run by Amgen, completed.
ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer is a phase 2 interventional study registered as NCT00261313 by Amgen, with 80 participants recorded, started 2005-12 and reaching its primary completion in 2007-06. Interventions recorded: Neulasta, Aranesp. Conditions recorded: Breast Cancer.
Linked to the drug Darbepoetin alfa because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Darbepoetin alfa, Pegfilgrastim and the tag pipeline.
Shares Pegfilgrastim, Male breast cancer, Breast cancer (all types) and the tag pipeline.
Shares Male breast cancer, Breast cancer (all types) and the tag pipeline.
Shares Male breast cancer, Breast cancer (all types) and the tag pipeline.
Shares Darbepoetin alfa and the tag pipeline.
Shares Pegfilgrastim, Breast cancer (all types) and the tag pipeline.
Shares Pegfilgrastim, Breast cancer (all types) and the tag pipeline.
Shares Pegfilgrastim, Breast cancer (all types) and the tag pipeline.